CTRI/2021/07/035233已完成2 期
A Phase 2, multicentric, randomized, double blind, prospective, comparative, placebo controlled, clinical trial to evaluate efficacy and safety of LifeViroTreat inhalation in mild nCOVID-19 infected patient. - 2021-0602
Supreme Industries0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.RT-PCR positive for nCOVID-19 within last 72 hours
- •2.Male and female patients with age above 18 years and below 65 years of age.
- •3.Patient willing to provide informed consent to participate into the trial.
- •4.Patient able to comply requirement of study and protocol.
- •5.Patient having SpO2 > 94 %, Respiratory rate < 24/min and temperature < 104 Ã?°F
排除标准
- •1Known hypersensitivity or idiosyncratic reaction to Chlorine or any of related substance or ingredient of the formulation.
- •2Patient having past history of respiratory disorder like COPD, Asthma etc.
- •3Patient is on medication before tested nCOVID 19 positive for respiratory disease or disorder (other than viral infection).
- •4Patients who are diagnosed and/or on treatment for venous thromboembolism, ischemic heart disease, myocardial infarction, congestive cardiac failure, unexplained vaginal bleeding with suspicion of serious underlying condition, history of breast or cervical cancer, malignant tumor
- •5Patient of Hypertension and/or Diabetes who was not on stable treatment in past 3 month.
- •6Patient was on immunomodulatory drug
- •7Have participated in other clinical study related to nCOVID 19
- •8Patients with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.
- •9Known history of Chronic Kidney disease
- •10Known history of Chronic Liver disease
- •11Nursing mother or pregnant women
研究者
相似试验
已完成
2 期
A Phase 2, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open label extensioNL-OMON53447Sanofi BV6
进行中（未招募）
1 期
Phase 2 trial, conducted in more than one site, in which no one knows the treatment assigned to the patient to evaluate the effect against pain and the safety of of the study drug, DFL24412, respect a control drug (Ketoprofen Lysine Salt, in patient with chronic low back paiChronic Low Back PainMedDRA version: 21.0Level: LLTClassification code 10052430Term: Chronic lumbagoSystem Organ Class: 100000004859EUCTR2021-001629-38-ITDOMPé FARMACEUTICI S.P.A.150
进行中（未招募）
1 期
Phase 2 trial, conducted in more than one site, in which no one knows the treatment assigned to the patient to evaluate the effect against pain and the safety of the study drug, DFL24412, respect a control drug (Ketoprofen Lysine Salt), in patient with chronic low back paiChronic Low Back PainMedDRA version: 21.0Level: LLTClassification code 10052430Term: Chronic lumbagoSystem Organ Class: 100000004859EUCTR2021-001629-38-ESDompè Farmaceutici S.p.A.150
招募中
2 期
A clinical trial to study the adjunctive effects of YKP3089 in patients with treatment resistant partial onset seizures.CTRI/2012/03/002500SK Life Science Inc200
进行中（未招募）
1 期
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetesew-onset Type 1 DiabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-002966-15-DEDompe farmaceutici s.p.a.75